The CDC cautions on the use of mRNA COVID-19 vaccines in persons who have a history of immediate allergic reaction to any injectable therapy or other vaccine, but state that the benefit of vaccination outweighs the risks in most individuals. The CDC, however, reports that a risk assessment should be done prior to vaccination, and that the vaccination procedure should include a 30-minute observation period post-vaccination. Consultation with an allergist-immunologist is also advised by the CDC.
In clinical trials, persons who have previously received dermal fillers experienced swelling at or near the site of filler injection. Persons with a history of receipt of dermal filler may be a higher risk of complications following mRNA COVID-19 vaccination.
Persons who have pre-existing immunity to SARS-CoV-2 may also be at increased risk of severe reactogenicity following mRNA COVID-19 vaccination. In a study conducted by researchers from the Icahn School of Medicine at Mount Sinai, persons with pre-existing immunity to SARS-CoV-2 who received mRNA COVID-19 vaccines were found to have significantly higher rates of systemic reactions when compared to those who were not immune at the time of vaccination. Systemic reactions included fatigue, headache, chills, fever, joint or muscle pains.
Children and adults with a history of Multisystem Inflammatory Syndrome (MIS-C and MIS-A) may be at an increased risk of adverse events following COVID-19 vaccine. There is a lack of information on the effects of COVID-19 vaccine in children with a history of MIS-C, a rare condition involving a dysregulated immune response following SARS-CoV-2 infection in children. Similarly, data is also lacking on the risks of COVID-19 vaccination on adults with a history of MIS-A, a similar condition to MIS-C. Despite the lack of safety data on the use of COVID-19 vaccination in this population, the CDC reports that experts consider the benefits of vaccination to outweigh any potential risks.
The CDC, however, states that the decision to administer additional COVID-19 vaccines in children and adults who develop MIS following COVID-19 vaccination should involve consultation between the patient and/or guardian and the clinical care team or specialist. Consultation with Clinical Immunization Safety Assessment COVIDvax project may also be considered.